Q-omics provides the consensus-scored KY profile across patient tissues and cancer cell-line models. KY expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KY is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, KY RNA expression shows 15,400 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, THCA, and TGCT as cancer lineages where KY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KY survival associations across molecular data types. KY RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KY RNA expression–survival associations across cancer types. High KY expression shows unfavorable associations in UVM, SKCM, COAD, LIHC, LUAD and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for KY RNA expression.
This table summarizes KY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KY shows lower tumor expression in THCA, BLCA, HNSC, KICH, KIRC and UCEC. The THCA box plot shows higher KY RNA expression in normal versus tumor tissue (log2 FC = −1.893, t-test p < 0.001).
This table shows molecular features associated with KY in patient tissues and cancer cell lines. In patient samples, KY shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
